Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis

Gan, Xiaoning; Lin, Xian; He, Rong‐Quan; Lin, Xinggu; Wang, Hanlin; Yan, Liyan; Zhou, Hong; Qin, Hui; Chen, Gang

doi:10.1155/2016/5259602

Cited by 25 publications

(26 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In China, BLCA was the thirteenth most common cancer with a total number of 80, 500 cases in 2015 [3]. The mechanisms of BLCA however remain largely unclear, which has led to the paucity of specific biomarkers for screening, surveillance, or prognostic stratification of BLCA [4][5][6][7][8][9][10]. Hence, there is an urgent need to identify new reliable biomarkers related to prognosis.…”

Section: Introductionmentioning

confidence: 99%

RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update

Huang²,

et al. 2018

Cell Physiol Biochem

Self Cite

View full text Add to dashboard Cite

Background/Aims: Current practical advances in high-throughput data technologies including RNA-sequencing have led to the identification of long non-coding RNAs (lncRNAs) for potential clinical application against bladder urothelial cancer (BLCA). However, most previous studies focused on the clinical value of individual lncRNAs, which has limited the potential for future clinical application. Methods: In this study, RNA-sequencing data of lncRNAs was downloaded from The Cancer Genome Atlas database. Risk score was constructed based on survival-associated lncRNAs identified using differential expression analysis as well as univariate and multivariate Cox proportional hazards regression analysis. Receiver operating characteristic and Kaplan-Meier curve analyses were employed to evaluate the clinical and prognostic value of risk scores. Bioinformatics analyses were used to investigate the potential mechanisms of newly identified lncRNAs. Results: Among 2,127 differentially expressed lncRNAs (DELs), four new lncRNAs (AC145124.1, AC010168.2, MIR200CHG, and AC098613.1) showed valuable prognostic effects in BLCA patients. More importantly, the four-DEL-based risk score had the potential to become an independent marker for the survival status prediction of BLCA patients. Distinct co-expressed genes and signaling pathways were identified when BLCA was categorized into low- and high-risk groups. Furthermore, a protein-coding gene, HIST4H4 was found only 68 bp from the AC010168.2 DEL. HIST4H4 expression level was evidently up-regulated and positively correlated with AC010168.2 in BLCA patients. Conclusion: This in silico investigation pioneers the future investigation of the utility of prognostic lncRNAs for BLCA.

show abstract

Section: Introductionmentioning

confidence: 99%

RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update

Huang²,

et al. 2018

Cell Physiol Biochem

Self Cite

View full text Add to dashboard Cite

show abstract

“…It is a cyclin-dependent kinase inhibitor. Loss or mutation of p16 gene would then result in loss of control over pRb phosphorylation, causing cell cycle progression (149)(150)(151)(152).…”

Section: Biomarkersmentioning

confidence: 99%

Staging and tumor biological mechanisms of lymph node metastasis in invasive urinary bladder cancer

Aljabery¹

2017

Linköping University Medical Dissertations

View full text Add to dashboard Cite

Aim: To study the possibility of detecting lymph node metastasis in locally advanced urinary bladder cancer (UBC) treated with radical cystectomy (RC) by using preoperative positron emission tomography/computed tomography (PET/CT) and peroperative sentinel node biopsy (SNB) technique. We also investigate the clinical significance of macrophage traits expression by cancer cells, M2-macrophage infiltration (MI) in tumor stroma and the immunohistochemical expression of biomarkers in cancer cells in relation to clinico-pathologic data. Patients and Methods:We studied prospectively 122 patients with UBC, pathological stage pT1-pT4 treated with RC and pelvic lymph node dissection (PLND) during [2005][2006][2007][2008][2009][2010][2011] at the Department of Urology, Linköping University Hospital. In the first study, we compared the results of preoperative PET/CT and conventional CT with the findings of postoperative histopathological evaluation of lymph nodes (LNs). In the second study we investigated the value of SNB technique for detecting pathological LNs during RC in patients with UBC. We also examined the significance of the primary tumor location in the bladder in predicting the site of LN metastases, and the prognostic significance of lympho-vascular invasion (LVI) and lymph node metastasis density (LNMD) on survival. In the third study, we investigate the clinical significance of macrophage infiltration (MI) in tumor stroma and macrophage-traits expression by tumor cells. In the fourth study, we investigate the cell cycle suppression pro-

show abstract

“…18 Although the data regarding the prognostic value of cyclin D1 is equivocal, a subgroup analysis in a study of 150 BCa patients revealed that over expression is considered as a predictor for lower progression rate and eventually better survival. 19 Cox’s multivariate analysis selected cyclin D3 as an independent predictor of progression-free survival together with tumor size in patients with Ta/T1 BCa.…”

Section: Cell Cycle Regulatorsmentioning

confidence: 99%

Urinary bladder cancer: biomarkers and target therapy, new era for more attention

et al. 2016

View full text Add to dashboard Cite

Currently, bladder cancer (BCa) evaluation depends mainly on traditional clinicopathological parameters encompassing tumor stage and grade, which will not reflect the behavior of the disease. Diverse molecular alterations are responsible for the heterogeneous course. The differences in molecular pathogenesis between non-invasive BCa and invasive BCa have been recognized. Molecular biomarkers are promising to predict progression and survival. The management of advanced BCa remains somewhat primitive in comparison with other more common malignancies. This topic will discuss the molecular pathways, biomarkers and potential targets that may improve the outcome in BCa.

show abstract

Prognostic and Clinicopathological Significance of Downregulated p16 Expression in Patients with Bladder Cancer: A Systematic Review and Meta-Analysis

Cited by 25 publications

References 35 publications

RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update

RNA-Sequencing Data Reveal a Prognostic Four-lncRNA-Based Risk Score for Bladder Urothelial Carcinoma: An in Silico Update

Staging and tumor biological mechanisms of lymph node metastasis in invasive urinary bladder cancer

Urinary bladder cancer: biomarkers and target therapy, new era for more attention

Contact Info

Product

Resources

About